The oncology pipeline has never been more diverse. Beyond the established frontiers of immunotherapy and antibody-drug conjugates, a broad and rapidly expanding landscape of novel mechanisms - cell cycle inhibitors, epigenetic modifiers, KRAS inhibitors, protein degraders, peptide-drug conjugates, and more - is generating early clinical readouts across tumor types. Keeping pace with this volume of emerging data is a challenge for even the most well-resourced drug development teams.
ONCrg's Emerging Clinical Signals (ECS) report cuts through the noise. By systematically tracking Phase I and I/II basket trial presentations from AACR, ASCO, and ESMO, Emerging Clinical Signals (ECS) surfaces the efficacy and safety signals that matter most - whether a promising new target is showing early tumor-agnostic activity, or an emerging toxicity pattern warrants a closer look. Thus, Emerging Clinical Signals (ECS) provides an efficient, expert-curated window into where the next wave of oncology therapeutics may be headed.
